Drug profile · INN
asciminib
SCEMBLIX
asciminib (SCEMBLIX) is a bcr/abl fusion protein inhibitor. Associated with Novartis Pharmaceuticals.
EMA: approved TGA: approved Antineoplastic and immunomodulating agents (L01) L01EA06
Patents linked 0
Pipeline programs 12
News articles 0
Drug details — asciminib
- Class
- Antineoplastic and immunomodulating agents (L01)
- Route
- —
- Patents
- 0
- Programs
- 12
- Data quality
- 0.83
Quick answer
asciminib (SCEMBLIX) is a bcr/abl fusion protein inhibitor. Associated with Novartis Pharmaceuticals.
Key facts
INN asciminib
Brand SCEMBLIX
Mechanism Bcr/Abl fusion protein inhibitor
Target Tyrosine-protein kinase ABL1
Therapeutic class Antineoplastic and immunomodulating agents (L01)
ATC code L01EA06
Originator Novartis Pharmaceuticals
Mechanism of action
Bcr/Abl fusion protein inhibitor
Primary target: Tyrosine-protein kinase ABL1
Approval history
| Authority | Status | Date |
|---|---|---|
| EMA | approved | — |
| TGA | approved | — |
Pipeline programs
Related & competitor drugs
Frequently asked questions
What is asciminib?
asciminib (SCEMBLIX) is a bcr/abl fusion protein inhibitor. Associated with Novartis Pharmaceuticals.
What is the brand name for asciminib?
SCEMBLIX is a marketed brand name for asciminib. Check FDA Drugs@FDA for the current US label holder and prescribing information.